Shots:

• The companies plan to conduct a P-I/IIa trial assessing the safety and anti-tumor activity of SNK01 + gemcitabine/carboplatin or gemcitabine/carboplatin + Erbitux (cetuximab) in patients with LA or mNSCLC after prior TKI therapy
• NKMax will sponsor the study while Merck KGaA will supply cetuximab (250 mg/m2- wq- IV) for P- I/IIa trial in NSCLC patients. The 1EPs of the study is to assess the safety and drug tolerance of SNK01 while 2EPs is to get efficacy assessments on the combination treatments
• Both the companies will have access to the data of the clinical study

  Ref: GlobeNewswire | Image: Merck KGaA